Fujirebio and Agappe Forge Strategic Partnership in CLIA-Based Immunoassay Solutions

This partnership will drive innovation in the immunology equipment sector, specifically for the Mispa i60 and Mispa i121.

Fujirebio will provide the Mispa i60 & i121 equipment along with essential reagent raw materials, while Agappe takes charge of developing and manufacturing dedicated reagents, ensuring compliance with all regulatory standards. 

The Supply and License Agreement, inked in March 2023, has propelled the project into its advanced stages of technical transfer, with the product launch scheduled for June 2024.

This initiative encompasses a phased release of various  clinical parameters, spanning segments such as Oncology, Thyroid, Cardiac, Fertility, and Infectious Diseases. The partnership also includes the incorporation of Fujirebio's novel biomarkers for Alzheimer’s and other neurodegenerative diseases.

Equally noteworthy is the decision to market the analyzers and reagents under Agappe’s brand, marking Agappe as the first Indian company to offer a complete Chemiluminescence Solution with locally manufactured reagents.

The collaboration is fueled by a shared vision, aiming to not only bolster India's immunoassay market expansion but also revolutionize and elevate immunoassay solutions within the country.

This partnership with Agappe, a renowned market leader in Clinical Chemistry, Hematology, Immunochemistry, and Point of Care in India, will expedite our CDMO strategy in one of the most crucial and fastest-growing countries globally,” Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc said.

Thomas John, Managing Director, Agappe expressed that the collaborative efforts are advancing exceptionally, underscoring a mutual dedication to innovation.

"Harnessing the synergies between Agappe and Fujirebio, we are committed to introduce unparalleled, cost-effective Chemiluminescence solutions, thereby establishing new industry benchmarks and elevating healthcare standards nationwide," he said.